What happened with SLXN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Silexion Therapeutics Corp is a clinical-stage biotechnology company developing treatments for cancers driven by KRAS mutations. Its initial focus is locally advanced pancreatic cancer that cannot be surgically removed, specifically tumors with KRAS G12D or G12V mutations. Its lead candidate, SIL204, uses small interfering RNA, or siRNA, to break down the genetic instructions tumor cells use to make mutated KRAS protein.
The company plans to combine SIL204 injections directly into tumors and under the skin with standard chemotherapy. This remains a treatment under development, not an approved product. Its approach depends on delivering the RNA safely into cancer cells and demonstrating that it works in patients; supporting evidence remains preliminary.
Silexion has not yet generated revenue. Equity investors and royalty-bearing grants from Israel’s Innovation Authority have supplied most of its funding, and continued development requires additional capital. It relies on outside manufacturers and research organizations to supply its candidates and run studies. Product sales would require regulatory approval, which it has not obtained.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Revolution Medicines is developing RAS-blocking drugs for G12D, G12V and other cancers that overlap with Silexion Therapeutics Corp’s SIL204, which aims to stop production of mutant KRAS protein. Watch results for its G12D drug zoldonrasib and G12V drug RMC-5127, the mutations in Silexion’s initial pancreatic-cancer focus.
Erasca’s drugs targeting multiple KRAS or RAS variants compete for the G12D and G12V cancers Silexion Therapeutics Corp aims to treat by silencing KRAS. Watch clinical results for ERAS-4001: its activity against G12D and G12V has so far been reported in preclinical models, not patients.
BridgeBio Oncology Therapeutics is developing drugs that block cancer-driving signals in RAS-driven and KRAS-mutant tumors, overlapping with the cancers Silexion Therapeutics Corp targets by silencing KRAS. Its plans to combine inhibitors in KRAS-mutant tumors are worth watching; it has no approved products or revenue from its drug candidates.
Elicio Therapeutics offers another test of KRAS-directed treatment in pancreatic cancer through immunotherapy, while Silexion Therapeutics Corp aims to silence KRAS in initially unresectable, locally advanced disease. Watch ELI-002 7P’s Phase 2 pancreatic-cancer results, but distinguish the treatment settings: Elicio’s earlier ELI-002 2P trial treated patients at high relapse risk after surgery and chemotherapy.
Adlai Nortye’s oral drug AN9025 blocks multiple forms of active RAS, offering a competing approach to cancers Silexion Therapeutics Corp targets by stopping mutant KRAS production. Watch AN9025’s Phase I results: the potency and broad antitumor activity Adlai Nortye reports so far come from laboratory and animal models.
Revolution Medicines, Inc. earningsRVMD
Revolution Medicines’ report will show how its G12D and G12V drugs are performing in patients, offering a read on competition for the cancers Silexion Therapeutics Corp aims to treat with SIL204.
Look for clinical data on zoldonrasib for G12D and RMC-5127 for G12V, especially activity and safety in patients; laboratory or animal findings are not patient evidence. Clear activity with acceptable safety would support a drug-treatment path for these mutations and raise the competitive bar for SIL204. Limited activity or safety problems would weaken that competing path, but would not show that SIL204 works.
Silexion Therapeutics Corp earningsThis company
Silexion Therapeutics Corp has no approved product or revenue, so this report will show whether its cash and financing can keep SIL204 clinical development moving.
Read operating cash use and cash on hand alongside any new financing, then check the SIL204 trial update. Manageable cash use, funding secured and trial progress would leave Silexion better positioned to keep developing the drug. Faster cash use without new funding, especially alongside stalled trial progress, would point to a funding gap that could force it to raise capital, cut back or delay development.
